I. OverviewII. Epidemiology and Etiology
(A) Epidemiology
(II) etiology.
Table 1 Common hereditary renal cell carcinoma and clinical manifestations
III. Histopathology
(A) Gross pathology.
(B) Classification.
Table 2 2016 WHO histological classification of renal cell tumor pathology
1. characteristics of common renal cell carcinoma pathological types
(1) clear cell renal cell carcinoma
(2) papillary renal cell carcinoma(3) susceptible cell carcinoma
(4) low malignant potential multifocal cystic kidney tumor
(5) collecting ductal carcinoma and renal medulla
2. Characteristics of pathological types of rare renal cell carcinoma
(1) MiT family metastatic carcinoma
(2) acquired renal cyst-associated renal cell carcinoma
(3) clear cell papillary renal cell carcinoma
(4) hereditary smooth muscle tumor disease and renal cell carcinoma-associated renal cell
(5) succinate dehydrogenase-deficient renal cell carcinoma
(6) tubular cystic carcinoma(7) mucinous tubular and spindle cell carcinoma
(8) renal cell carcinoma, unclassified(3) graded.
Table 3 WHO/ISUP Nuclear Grading Criteria for Renal Cell Carcinoma, 2016 Edition(iv) staging.
Table 4 2017 8th edition AJCC TNM staging for renal cell carcinomaTable 5 Clinical staging/prognostic subgroups for renal cell carcinoma
IV. Diagnosis
(A) clinical manifestations.
(B) laboratory tests.
(C) imaging examinations.
Table 6 Bosniak classification and management of renal cystic masses
V. Prognostic evaluation of advanced/metastatic renal cell carcinoma
Table 7 Prognostic risk assessment criteria for advanced renal cell carcinoma
VI. Treatment
(A) surgical treatment.
Table 8 Mayo clinical classification of tumor emboli five-level classification
(B) interventional therapy.
1. embolization therapy
2. ablation therapy
(iii) active monitoring
(iv) medication.
(v) Chinese herbal medicine treatment.
(vi) radiotherapy.
(vii) Common adverse reactions to targeted drugs and their management.
Table 9 Grading of hypertension associated with targeted drugs for renal cell carcinoma
Table 10 Grading of hematologic toxicity of targeted therapies for renal cell carcinoma
Table 11 Grading of hand-foot syndrome and skin toxicity of targeted therapy for renal cell carcinoma
Table 12 Grading of gastrointestinal adverse effects of targeted therapies for renal cell carcinoma
Table 13 Grading of hypothyroidism in targeted therapy for renal cell carcinoma
(viii) treatment of limited renal cell carcinoma
(ix) Treatment of locally progressive renal cell carcinoma.
(X) Treatment of advanced/metastatic renal cell carcinoma.
1. surgical treatment
2. Systemic therapy
(1) Clinical trials
(2) Systemic therapy for clear cell-dominant renal cell carcinoma
(1) First-line treatment of clear cell predominant renal cell carcinoma.
(2) Follow-up treatment of clear cell predominant renal cell carcinoma
Table 14 Pharmacologic treatment strategies for metastatic or unresectable clear cell renal cell carcinoma(3) Systemic therapy for non-clear cell renal cell carcinoma
Table 15 Pharmacologic treatment strategies for metastatic or unresectable non-clear cell renal cell carcinoma3. palliative radiotherapy
4. Principles of treatment for metastases at specific sites
VII. Follow-up
(A) Postoperative follow-up.
(B) Follow-up of patients with local treatment.
(C) Follow-up of patients with advanced disease.